Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe hepatocellular dysfunction following cyproterone acetate therapy.

B T Parys1, S Hamid, R G Thomson

  • 1Department of Urology, Royal Preston Hospital, Preston.

British Journal of Urology
|March 1, 1991
PubMed
Summary

Cyproterone acetate (CPA) can cause severe liver damage, including fatal hepatitis, in patients with advanced prostate cancer. This highlights the risks associated with long-term CPA treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of paraneoplastic antibodies in United Kingdom - An estimate from a regional centre.

Clinical neurology and neurosurgery·2025
Same author

[Deferoxamine maculopathy].

Journal francais d'ophtalmologie·2025
Same author

Parental Relationship and School Performance of Children.

Mymensingh medical journal : MMJ·2024
Same author

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Deciphering the inflection points to achieve proficiency for each procedure step during training in laparoscopic appendicectomy.

BJS open·2021
Same author

Knowledge of final-year medical students about oral and maxillofacial surgery: a two-centre study.

The British journal of oral & maxillofacial surgery·2018

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Cyproterone acetate (CPA) is a standard treatment for advanced prostate cancer.
  • While generally safe, CPA is associated with potential liver toxicity upon prolonged use.

Observation:

  • This report details three cases of severe hepatocellular damage in patients undergoing CPA therapy.
  • Two of these cases resulted in fatal fulminant hepatitis.

Findings:

  • Cyproterone acetate can induce severe liver injury, a serious adverse effect.
  • The risk of fatal hepatotoxicity may be underestimated in patients receiving long-term CPA treatment.

Implications:

  • Clinicians should be vigilant for signs of liver toxicity in patients on CPA.

Related Experiment Videos

  • Further research into CPA's hepatotoxicity mechanisms and risk mitigation strategies is warranted.